AU Patent

AU2004257636B2 — Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists

Assigned to Neurocrine Biosciences Inc · Expires 2011-01-06 · 15y expired

What this patent protects

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R<SUB>1a</SUB>, R<SUB>1b</SUB>, R<SUB>2a</…

USPTO Abstract

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R<SUB>1a</SUB>, R<SUB>1b</SUB>, R<SUB>2a</SUB>, R<SUB>2b</SUB>, R<SUB>3</SUB>, R<SUB>4</SUB>, R<SUB>5</SUB>, R<SUB>6</SUB>, R<SUB>7 </SUB>and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2004257636B2
Jurisdiction
AU
Classification
—
Expires
2011-01-06
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.